Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Cr4.5
Chrom – Forschung
Hilft wahrscheinlich
32 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Chrom scheint in 9 von 12 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2007–2026 mit einer typischen Studiengröße von 637 Teilnehmenden.
Basierend auf 32 Studien · 24 Meta-Analysen · 3 RCTs · 37,346 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
9geholfen3unklar· 20 weitere ohne bewertete Effektdaten
Nach Outcome
Glucose & metabolicBescheidene, wenig gesicherte Verbesserungen bei Nüchternglukose und HbA1c, hauptsächlich bei Typ-2-Diabetes · 6-12 Wochen · Unterstützt die Insulinsignalgebung; Nutzen ohne Diabetes gering und unsicher · 4-12 Wochen
Hilft wahrscheinlich19 Studien
Cholesterol & lipids
Überwiegend Mechanismus / Beobachtung10 Studien
Women's health
Überwiegend Mechanismus / Beobachtung6 Studien
Weight managementBehauptungen zu Heißhunger/Gewicht schwach; Übersichtsarbeiten finden keinen klaren Effekt auf die Körperzusammensetzung · 6-12 Wochen
Überwiegend Mechanismus / Beobachtung5 Studien
Inflammation
Hilft vermutlich5 Studien
Heart & blood pressure
Zu wenige bewertete Studien2 Studien
Safety profile
Zu wenige bewertete Studien2 Studien
In Zahlen
Aus 26 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
75%
über Studien hinweg
Untersuchte Personen
37k
typische Studie: 637 Personen
Stärkste Designs
27
24 gepoolt, 3 randomisiert
Zeigte Nutzen
75%
9/12 Studien
Untersuchte Populationen
Women with polycystic ovary syndrome3
Type 2 diabetes patients3
Type 2 diabetes mellitus patients2
Adults with type 2 diabetes1
Aktives Forschungsgebiet
27 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
200720162026
1PCOS symptoms improvementMeta-AnalyseCited 2×n=5,501 · very large study2025
Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.
Zhao G et al. · Reproductive biology and endocrinology : RB&E (2025)
Inositol significantly decreased total cholesterol and triglyceride levels, while curcumin was most effective in improving low-density and high-density lipoprotein cholesterol levels.
Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.
For improving obesity, sex hormone levels, inflammatory factors and oxidative stress indicators of PCOS patients, carnitine, chromium, and soy isoflavones are effective options, respectively.
2Fasting blood glucose reductionMeta-AnalyseCited 31×n=14,223 · very large study2023
Low to very low certainty evidence established chromium supplements as the most effective in reducing fasting blood glucose levels and homeostasis model assessment of insulin resistance (SUCRAs: 90...
Xia J et al. · Pharmacological research (2023)
Low to very low certainty evidence established chromium supplements as the most effective in reducing fasting blood glucose levels and homeostasis model assessment of insulin resistance (SUCRAs: 90.4% and 78.3%, respectively).
Vitamin K supplements ranked best in reducing glycated hemoglobin A1c and fasting insulin levels (SUCRAs: 97.0% and 82.3%, respectively), with moderate to very low certainty evidence.
Vanadium supplements ranked best in lowering total cholesterol levels with very low evidence certainty (SUCRAs:100%).
3Body weight reductionMeta-AnalyseCited 10×n=2,362 · very large study2023
Carnitine was relatively effective in reducing body mass, while chromium, Omega-3, and selenium were beneficial for improving glucose metabolism.
Hu X et al. · PeerJ (2023)
The network meta-analysis showed that carnitine, inositol, and probiotics reduced body weight and body mass index (BMI) compared to placebo, and carnitine outperformed the other supplements (SUCRAs: 96.04%, 97.73%, respectively).
Omega-3 lowered fasting blood glucose (FBG) (SUCRAs: 93.53%), and chromium reduced fasting insulin (FINS) (SUCRAs: 72.90%); both were superior to placebo in improving insulin resistance index (HOMA-IR), and chromium was more effective than Omega-3 (SUCRAs: 79.99%).
Selenium was potent in raising the quantitative insulin sensitivity index (QUICKI) (SUCRAs: 87.92%).
4Total cholesterol reductionMeta-AnalyseCited 17×n=7,605 · very large study2021
Our meta-analysis reveals that there was only an overall significant association between chromium supplementation with decreases in the concentration of TC.
Tarrahi MJ et al. · Pharmacological research (2021)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Our results of overall analysis show only a significant reduction in serum TC level in response to chromium supplementation (WMD: -0.17 mmol/l, 95 % CI: -0.27, -0.07, P = 0.001).
Our meta-analysis reveals that there was only an overall significant association between chromium supplementation with decreases in the concentration of TC.
Additionally, we found considerable evidence of subgroup analysis that support a significant lowering effect of chromium supplementation on TC, TG and VLDL.
6Total antioxidant capacityMeta-AnalyseCited 29×n=550 · large study2022
Chromium supplementation may improve OS parameters, however, due to high heterogeneity observed in the included studies, these findings should be interpreted with caution.
Morvaridzadeh M et al. · Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) (2022)
Spürbar Nutzen
← SchlechterKein EffektBesser →
The obtained results indicate that chromium supplementation significantly increases TAC (SMD: 0.46; 95 % CI: 0.08, 0.84; I2 = 00.0 % n = 2) and significantly decreases MDA levels (SMD: -0.46; 95 % CI: -0.86, -0.07; I2 = 52.4 % n = 5).
Chromium supplementation may improve OS parameters, however, due to high heterogeneity observed in the included studies, these findings should be interpreted with caution.
Large RCTs on various patient groups evaluating the impact of chromium supplementation are needed to allow an adequate generalization of the benefits of chromium on human health.
7Systolic blood pressure reductionSystematische ÜbersichtCited 7×n=637 · large study2021
The current meta-analysis, indicated that supplementation with chromium significantly decrease SBP and DBP.
Lari A et al. · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2021)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
The random-effects meta-analysis of 11 eligible RCTs with 637 participants demonstrated the significant decline in both SBP (WMD - 2.51 mmHg; 95% CI - 4.97 to - 0.05, p = 0.04) and DBP (WMD - 1.04 mmHg; 95% CI - 1.96 to - 0.12, p = 0.026) following supplementation with chromium.
Also, in stratification based on participants' health status, significant reduction in SBP only was seen in diabetic patients with chronic heart disease (CHD).
The current meta-analysis, indicated that supplementation with chromium significantly decrease SBP and DBP.
The results of the current meta-analysis study might support the use of chromium supplementation for the improvement of glycemic control indices in T2DM patients.
Asbaghi O et al. · Pharmacological Research (2020)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Results revealed significant reduction in FPG (weighted mean difference (WMD): -19.00 mg/dl, 95% CI: -36.15, -1.85, P = 0.030).
Significant reductions were also seen in insulin level (WMD: -12.35 pmol/l), HbA1C (WMD: -0.71 %, 95% CI: -1.19, -0.23, P = 0.004) and HOMA-IR (WMD: -1.53).
Twenty-eight studies reported fasting plasma glucose, insulin, HbA1C and HOMA-IR as an outcome measure.
9Body weight reductionMeta-AnalyseCited 20×n=1,316 · large study2019
Chromium supplementation was associated with some improvements in body composition in subjects with obesity/overweight.
Tsang C et al. · Clinical Obesity (2019)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Pooled analysis showed significant reductions in anthropometric indices associated with body composition; for weight loss (weighted mean difference [WMD]: -0.75 kg, 95% confidence interval [CI], -1.04, -0.45, P < 0.001).
Body fat percentage was reduced (WMD: -0.68%, 95% CI, -1.32, -0.03, P = 0.04) in individuals with overweight/obesity.
The effect size was medium and the clinical relevance of chromium as a weight loss aid remains uncertain.
The results of this experiment show that chromium supplementation had a positive effect on blood sugar control and various factors including weight, BMI, SBP, DBP, triglycerides, and waist circumference, and had an effective role in improving the level of liver enzymes.
Monfared V et al. · Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) (2025)
The results of this experiment show that chromium supplementation had a positive effect on blood sugar control and various factors including weight, BMI, SBP, DBP, triglycerides, and waist circumference, and had an effective role in improving the level of liver enzymes.
Gholami A et al. · Biological trace element research (2025)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Likely real
In contrast, chromium supplementation resulted in a non-significant decrease in serum levels of IL-6 (WMD = -0.63 pg/ml; 95% CI: -1.67, 0.4 pg/ml; P < 0.001).
Our study supports the beneficial effect of chromium supplementation on serum concentration of CRP and TNF-α, but our results showed that chromium supplementation non-significantly reduced the serum levels of IL-6.
However, it seems that chromium formulation, participants' BMI, sample size, and geographical region are strong variables that predict the effect of chromium supplementation on inflammatory mediators.
Georgaki MN et al. · Environmental geochemistry and health (2024)
Glycemic control markers, including FPG, insulin, HbA1C, and HOMA-IR levels, significantly decrease following chromium supplementation, mainly in studies with a longer intervention period.
Supplementing with chromium (Cr) indicated that could significantly improve lipid profile by raising high-density lipoprotein and lowering triglyceride and total cholesterol while having little effect on low-density lipoprotein.
However, most research findings include significant limitations, such as inconsistent dosage and type of chromium, formulation of supplements, and study duration.
Vajdi M et al. · Biological trace element research (2023)
However, subgroup analysis by the intervention dose suggested that chromium supplementation in doses higher than 500 µg/day could significantly decrease TG.
The available evidence proposes no beneficial effects of chromium intervention on blood lipids.
As a result, it cannot be used as a single therapy to treat adults with lipid abnormalities.
14Body weight changeMeta-AnalyseCited 7×n=14 · very small study2024
The meta-analysis suggests that chromium supplementation does not significantly reduce BW, BMI, WC, and FM in patients with T2DM.
Vajdi M et al. · Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) (2024)
Kein klarer Effekt
← SchlechterKein EffektBesser →
The results showed that chromium supplementation did not have any significant effect on FM (WMD = -0.43%; 95% CI -0.94, 0.09), BMI (WMD: 0.09 kg/M2, 95% CI: -0.03, 0.20), WC (WMD: -0.47 cm, 95% CI: -1.10, 0.16), and BW (WMD: -0.26 kg, 95% CI: -0.69, 0.16).
The meta-analysis suggests that chromium supplementation does not significantly reduce BW, BMI, WC, and FM in patients with T2DM.
Further RCTs with large-scale are required to determine the possible anti-obesity effects of chromium in patients with T2DM.
Kim Y et al. · Archives of pharmacal research (2022)
Chromium (HbA1c, FBG, and HOMA-IR), coenzyme Q10 (HbA1c and FBG), vitamin C (HbA1c and FBG), and vitamin E (HbA1c and HOMA-IR) significantly improved glycemic control.
Administration of chromium, coenzyme Q10, and vitamins C and E for T2DM significantly improved glycemic control.
Sensitivity analyses did not modify the pooled effects of pharmaconutrients on glycemic control.
16Biomarkers of inflammationMeta-AnalyseCited 23×2021
Overall, the results of this systematic review and meta-analysis imply that chromium supplementation may help to improve biomarkers of inflammation as markers of myocardial infarction.
Zhang X et al. · Complementary therapies in clinical practice (2021)
Overall, the results of this systematic review and meta-analysis imply that chromium supplementation may help to improve biomarkers of inflammation as markers of myocardial infarction.
18HbA1c reductionMeta-AnalyseCited 94×n=22 · very small study2014
The available evidence suggests favourable effects of chromium supplementation on glycaemic control in patients with diabetes.
Suksomboon N et al. · Journal of clinical pharmacy and therapeutics (2014)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Overall, chromium mono- and combined supplementation significantly improved glycaemic control (mean difference for HbA1c -0·55%; 95% CI -0·88 to -0·22%; P = 0·001, mean difference for FPG -1·15 mm; 95% CI -1·84 to -0·47 mm; P = 0·001).
In particular, chromium monotherapy significantly reduced triglycerides and increased HDL-C levels.
The available evidence suggests favourable effects of chromium supplementation on glycaemic control in patients with diabetes.
Chromium supplementation significantly improved glycemia among patients with diabetes.
Balk EM et al. · Diabetes Care (2007)
Among participants with type 2 diabetes, chromium supplementation improved glycosylated hemoglobin levels by -0.6% (95% CI -0.9 to -0.2) and fasting glucose by -1.0 mmol/l (-1.4 to -0.5) but not lipids.
There was no benefit in individuals without diabetes.
Larger effects were more commonly observed in poor-quality studies.
Ye J, Cen S, Qi Q, Wang C, Wang J, Wang J, Yaping G, Wang J. · BMC endocrine disorders (2026)
Mineral supplementation was associated with significant reductions in fasting blood glucose (SMD = − 0.34, p < 0.001), fasting insulin (SMD = − 0.72, p < 0.001), and HOMA-IR (SMD = − 0.75, p < 0.001).
In addition, total cholesterol (SMD = − 0.35, p < 0.001) and triglyceride levels (SMD = − 0.58, p < 0.001) were significantly reduced.
A small but statistically significant reduction in HDL levels was also observed (SMD = − 0.19, p = 0.04).